Search

everythinglearnresearchcommunity

for

Search:↓

Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.

A new treatment called SAMiRNA-AR68 increases hair count in people with hair loss, showing similar results to existing treatments but without side effects.

Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.

Medium-dose prednisolone pulse therapy is effective and safe for multifocal alopecia areata but not for more severe forms.

Combining imiquimod with diphenylcyclopropenone may improve treatment outcomes for alopecia areata patients who don't respond to diphenylcyclopropenone alone.

Tofacitinib helped regrow hair in most patients with severe hair loss.

SVF and PRP improve hair loss, but SVF causes more side effects.

JAK inhibitors are effective for severe alopecia areata but need better strategies for long-term use and personalized treatment.

A woman with a skin disorder was found to have hepatitis C, which may be linked, and was safely treated with methotrexate.

JAK inhibitors are effective for treating alopecia areata, with most patients seeing hair growth after treatment.

Both treatments improved hair quality and thickness equally, with mild side effects.

Targeted cytokine treatments may help with alopecia areata, but more research is needed.

New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.

Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.

TYK2 inhibitors show promise for treating cancer and autoimmune disorders.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

LMWP-PDGFA shows promise for improving hair health and treating hair loss with fewer side effects.

Long-term high-dose fluconazole can cause reversible hair loss.

A new device, IVL-PPF Microsphere®, was created to deliver a hair loss drug for up to 3 months with one injection, potentially replacing daily pills.

New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.

Cyproterone acetate with estradiol improved women's self-confidence and emotional well-being without a difference between oral or transdermal methods, but younger women preferred the oral method.

Booster shots of mRNA vaccines for COVID-19 increased protective antibodies without worsening autoimmune skin conditions in patients.

Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Hydroxychloroquine may cause false results in tuberculosis tests for patients with autoimmune skin diseases.

A new hydrogel treatment reduces inflammation and promotes hair growth in alopecia areata.